Playback speed
10 seconds
ACC 2018: What are the Takeaways of the ODYSSEY Outcomes Trial?
441 views
June 14, 2018
Dr. Steve Nissen, Cleveland Clinic Chairman of Cardiovascular Medicine, discusses the results the ODYSSEY trail ...
read more ↘ looking at the PCSK9 inhibitor alirocumab in patients who had a prior acute coronary syndrome and were on maximum statin therapy. Dr. Nissen provides us insight into the results and take-away message.
↖ read less
read more ↘ looking at the PCSK9 inhibitor alirocumab in patients who had a prior acute coronary syndrome and were on maximum statin therapy. Dr. Nissen provides us insight into the results and take-away message.
↖ read less
Login to view comments.
Click here to Login